IPOGrid
0001938571
IPO filing research
ADAPTIN BIO, INC.
Biological Products, (No Diagnostic Substances) · APTN
follow-on
filed
OTCQB
S-1
ADAPTIN BIO, INC. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-08-28. Current deal snapshot: exchange OTCQB.
Filing Timeline
SEC EDGAR
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows S-1/A in the pre-IPO sequence.
382,400 shares
common stock · Exchange OTCQB · Ticker APTN · 38,240 shares of common stock underlying placement agent warrants · Selling stockholders only · Use of proceeds Proceeds from placement agent warrants exercised for cash · Flags warrants
2026-08-28 · 0001213900-26-095034
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
1,901,482 shares
common stock · Exchange OTCQB · Ticker APTN · warrants held by selling stockholders · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds
2026-08-25 · 0001213900-26-093549
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
First tracked pre-IPO filing for this issuer.
Price $4.40 · 1,400,342 shares · Gross proceeds $6,161,505
common stock · Exchange OTCQB · Ticker APTN · Each Unit consists of one share of common stock and two warrants · Warrants to purchase common stock at $4.40 and $6.553 per share, with terms of one year and five years respectively · Selling stockholders only
2026-08-20 · 0001213900-26-092107
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2026-07-22 · 9999999995-26-002384
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Adaptin Bio, Inc. filed an amended Form 10-K/A for the fiscal year ended December 31, 2025, updating Item 15(b) and Exhibit 23.1 to include an updated consent from its independent auditor, WithumSmith+Brown, PC. The filing references the prospectus supplement and notes the company's stock is quoted on the OTCQB Venture Market. The document includes certifications from executives and disclosures about financial risks.
2026-06-12 · 0001213900-26-068357
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
1,901,482 shares
common · Exchange OTCQB · Ticker APTN · Selling stockholders only · Use of proceeds Selling stockholders will receive the proceeds from the sale of their shares
2026-05-18 · 0001213900-26-058479
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Price $4.40 · 1,901,482 shares · Gross proceeds $6,161,505
common stock · Unit includes 1 share, A Warrant for 1 share at $4.40, and B Warrant for 0.5 share at $6.60 · A Warrant: $4.40 exercise price, 1-year term; B Warrant: $6.60 exercise price, 5-year term · Selling stockholders only · Use of proceeds Working capital, debt repayment, and other operational expenses · Flags units, warrants · Underwriters placement agent
Adaptin Bio, Inc. filed a 424B3 registration statement disclosing updated financial information, including unaudited condensed consolidated financial statements as of September 30, 2025. The company reports significant operating losses, with a net loss of $3.8M for the nine months ended September 30, 2025. The filing highlights the completion of a merger with Unite Acquisition 1 Corp., resulting in a reverse recapitalization and name change to Adaptin Bio, Inc. The company remains in the early stages of drug development for CNS disorders, with ongoing reliance on external financing to sustain operations. Cash reserves are $579K as of September 30, 2025, with substantial accumulated deficits and continued operating losses expected.
2025-11-17 · 0001213900-25-111384
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Price $4.40 · 4,134,565 shares · Gross proceeds $8,366,521
common · 2,233,083 shares of common stock underlying warrants held by the selling stockholders · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholders with no issuer proceeds
Adaptin Bio, Inc. filed a prospectus supplement (424B3) updating its registration statement to include information from a Form 8-K dated October 6, 2025. The filing relates to the sale of 1,901,482 shares of common stock by selling stockholders and 2,233,083 shares underlying warrants. The company notes no active trading market for its shares and highlights significant investment risks. The supplement incorporates amendments to executive employment agreements, including salary adjustments and anti-dilution provisions for key officers.
2025-10-07 · 0001213900-25-097028
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Price $4.40 · Range $4.40 to $4.40 · 1,901,482 shares · Gross proceeds $6,161,505
common · Exchange OTCQB · Ticker ADAP · Each Unit consists of one share of common stock, a warrant to purchase one share at $4.40, and a warrant to purchase 0.5 shares at $6.60 · Warrants to purchase 2,233,083 shares at $4.40 and $6.60 · Selling stockholders only · Use of proceeds to fund operations and working capital · Flags units, warrants · Underwriters placement agent
Adaptin Bio, Inc. filed a 424B3 prospectus containing unaudited financial statements as of June 30, 2025. The filing reflects a merger with Unite Acquisition 1 Corp., resulting in a recapitalization and name change to Adaptin Bio Operating Corporation. Financials show significant operating losses, with a $2.1M net loss for the six months ended June 30, 2025, and an accumulated deficit of $6.2M. The company remains a going concern, reliant on fundraising for operations and clinical development.
2025-08-15 · 0001213900-25-077176
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
1,901,482 shares
common stock · Ticker ADAP · (i) one share of Common Stock, (ii) a warrant representing the right to purchase one share of Common Stock, exercisable from issuance until one year after the respective closing of the Private Placement at an exercise price of $4.40 per share (an A Warrant ), and (iii) a warrant, representing the right to purchase one-half of a share of Common Stock, exercisable from issuance until five years after the respective closing of the Private Placement at an exercise price of $6.60 per whole share (a B Warrant ) · Warrants to purchase up to 2,233,083 shares of common stock · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the resale
2025-08-05 · 0001213900-25-071970
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
2025-08-04 · 9999999995-25-002464
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Selling stockholders only · Use of proceeds Selling stockholders intend to sell shares, with no proceeds going to the issuer · Flags warrants
2025-07-28 · 0001213900-25-068130
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Use of proceeds Proceeds will go to selling stockholders, with no issuer proceeds
2025-06-27 · 0001213900-25-058957
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
First tracked pre-IPO filing for this issuer.
Common Stock · Warrants may be issued upon a Qualified Offering · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, with no proceeds to the company
2025-05-16 · 0001213900-25-044585
Comparable Deals
20 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 20 using nearest neighbors.
Showing top 8 by similarity.
Attovia Therapeutics, Inc.
ATTO
same SICrecent IPO
Scribe Therapeutics, Inc.
SCTX
same SICrecent IPO
Odyssey Therapeutics, Inc.
ODTX
same SICrecent IPO
Hemab Therapeutics Holdings, Inc.
COAG
same SICrecent IPO
Vogenx, Inc.
VOGX
same SIC grouprecent IPO
BlossomHill Therapeutics, Inc.
BLSM
same SIC grouprecent IPO
Latigo Biotherapeutics, Inc.
LTGO
same SIC grouprecent IPO
Braveheart Bio, Inc.
BRVE
same SIC grouprecent IPO
Recent News
No recent news stored for this issuer.